# A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma

> **NCT03383406** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy

## Key facts

- **NCT ID:** NCT03383406
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383406, "A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03383406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*